Abstract:It is possible to repress amyloid precursor protein (APP) mRNA translation as a novel anti-amyloid pharmacotherapy for Alzheimer's Disease (AD). This therapeutic model is consistent with well-documented cases where AD pathology can be the genetic consequence of duplications of the APP gene. This genetic duplication caused increased brain APP dose leading to over-expression of Ab amyloid and then disease onset. These findings support our pharmacological goal to reduce APP expression. As due diligence, we showed that FDA drugs (i.e., paroxetine & N-acetyl cysteine) selectively reduced APP translation in neural and epithelial cells while maintaining compensatory APLP-1/-2 levels, but then these drugs also limited Aß production in vivo. Paroxetineis a well-known selective serotonin reuptake inhibitor (SSRI) and a clinical anti-depressant that was identified to inhibit APP 5'untranslated region (5'UTR)-luciferase reporter expression. We showed proof-of-concept that unlike other SSRIs, paroxetine exhibits a planar tricyclic aromatic benzodioxole structure and provided anti-amyloid activity in the brains of APP(Swe) transgenic mice. Additionally, posiphen, a + enantiomer of the well-tested anti-cholinesterase phenserine, passed phase I clinical trials for AD as an APP 5'UTR inhibitor. Encouraged by this, we screened the 110,000 compound molecular library at Harvard's Laboratory for Drug Discovery in Neurodegenerative Diseases that had been optimized to obtain pharmacologically favorable activity agents; for example small molecules that inhibit mesangial cell proliferation following three-dimensional pharmacophore modeling. From our screen, thirteen top leads shared chemical features pertinent to their potently blocking APP 5'UTR directed translation (IC-50: 1nM to ∼100nM). This correlated well with their selective suppression of APP expression in several neural cell lines. The top compounds of these APP 5'UTR inhibitors were 50-fold more potent blockers of Aß precursor translation than either paroxetineor posiphen. The most active lead was the ninth compound in the series, APP blocker-9 (“JTR-009”). Critically, JTR-009 effectively reduced APP levels in primary mouse E-18 cortical neurons at single nanomolar concentrations similar to that for the serum concentrations of effective clinical drugs. Our top APP translation blocker, JTR-009, is a planar tricyclic benzimidazole that could potentially intercalate into the single 146 base APP 5'UTR specific RNA stem loop. Confirming specificity, we are checking how JTR-009 blocks ribosome scanning of the APP 5'UTR to impede translation (Aß output) but not to interact with the 5'UTRs of APP-like protein (APLP-1/-2) mRNAs. We are currently determining the in vivo pharmacokinetics and tolerance of JTR-009, and we are completing a structure activity relationship (SAR) study of ten close analogs using primary cortical neurons from the B6-R1.40 genomic mouse model of AD.

The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen

Therapeutic Action of Translation Blockers on Expression of the Amyloid Precursor Protein As a Central Ferroxidase

Novel Therapeutic Horizons: SNCA Targeting in Parkinson's Disease

Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera

Novel 5 ' Untranslated Region Directed Blockers of Iron-Regulatory Protein-1 Dependent Amyloid Precursor Protein Translation: Implications for Down Syndrome and Alzheimer'S Disease

P2‐497: Mechanism of Action of App Translation Blockers: from Model to Human

Specific APP translation blockers as a therapeutic intervention for Alzheimer's disease

Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors

Effective lowering of α-synuclein expression by targeting G-quadruplex structures within the SNCA gene

Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management

Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson's disease management

Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology

Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation

Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson’s Disease

A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity

Genipin prevents alpha-synuclein aggregation and toxicity by affecting endocytosis, metabolism and lipid storage

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease

Exosome-mediated delivery of antisense oligonucleotides targeting -synuclein ameliorates the pathology in a mouse model of Parkinson's disease

Inhibitor Development for α-Synuclein Fibril's Disordered Region to Alleviate Parkinson's Disease Pathology

A Systematic RNAi Screen of Neuroprotective Genes Identifies Novel Modulators of Alpha-Synuclein-Associated Effects in Transgenic Caenorhabditis elegans

Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity